{"transactions":[{"id":706461,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant to purchase ADSs","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":5799,"price":16.16,"value":93711.84,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants remain exercisable until fully exercised."}],"balance_after":0,"derivative":{"exercise_price":0.0004,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":5799},"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706460,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant to purchase ADSs","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":15466,"price":16.16,"value":249930.56,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants remain exercisable until fully exercised."}],"balance_after":0,"derivative":{"exercise_price":0.0004,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":15466},"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706459,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant to purchase American Depositary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":1209,"price":32,"value":38688.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants remain exercisable until fully exercised."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2023-10-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":1209},"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706458,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":5799,"price":0.0004,"value":2.3196,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"balance_after":98241,"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706457,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":15466,"price":0.0004,"value":6.1864,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"balance_after":92442,"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":706456,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2026-07-17T10:03:07.000Z","date":"2026-07-07","kind":"exercise","planned":false,"acquired":true,"shares":1209,"price":8,"value":9672.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"balance_after":76976,"source":{"system":"sec-edgar","filing":"0001493152-26-033634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226033634/ownership.xml","form_type":"4"}},{"id":962861,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":231997,"price":0.4041,"value":93749.9877,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":231997,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":231997},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":962860,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":231997,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 231,997 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 241,437 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":231997,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":231997},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":962859,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"price":0.4041,"value":249999.6978,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":962858,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:56:47.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":618658,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 618,658 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 618,658 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":618658,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":618658},"source":{"system":"sec-edgar","filing":"0001493152-25-028418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028418/ownership.xml","form_type":"4"}},{"id":1193158,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:13.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043938","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043938/ownership.xml","form_type":"4"}},{"id":1193157,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:13.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043938","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043938/ownership.xml","form_type":"4"}},{"id":1214569,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":406250,"price":1.12,"value":455000.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":406250,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":406250},"source":{"system":"sec-edgar","filing":"0000950170-25-036486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036486/ownership.xml","form_type":"4"}},{"id":1214568,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":406250,"price":1.12,"value":455000.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":406250,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":406250},"source":{"system":"sec-edgar","filing":"0000950170-25-036486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036486/ownership.xml","form_type":"4"}},{"id":1214567,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:10.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":406250,"price":1.12,"value":455000.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depository Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 406,250 ADS  and accompanying Series A and Series B warrants to purchase up to 812,500 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":3031005,"source":{"system":"sec-edgar","filing":"0000950170-25-036486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036486/ownership.xml","form_type":"4"}},{"id":1307607,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T21:30:03.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":152672000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options have an exercise price of $0.000655 per Ordinary Share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":152672000,"derivative":{"exercise_price":0.0006,"exercise_date":"2025-01-03","expiration_date":"2035-01-03","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":152672000},"source":{"system":"sec-edgar","filing":"0000950170-25-002864","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025002864/ownership.xml","form_type":"4"}},{"id":1307606,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2025-01-07T21:30:03.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":208000,"price":0.0006,"value":124.8,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 3, 2025, the Reporting Person acquired 208,000 Ordinary Shares at a purchase price of $0.0006 per Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On January 3, 2025, the Reporting Person acquired 208,000 Ordinary Shares at a purchase price of $0.0006 per Ordinary Share."}],"balance_after":5249511500,"source":{"system":"sec-edgar","filing":"0000950170-25-002864","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025002864/ownership.xml","form_type":"4"}},{"id":1320295,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-12-30T21:30:06.000Z","date":"2024-12-27","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0.0005,"value":200.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 27, 2024 the Reporting Person acquired 400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 26, 2024, the Reporting Person acquired 3,200,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."}],"balance_after":5249303500,"source":{"system":"sec-edgar","filing":"0000950170-24-141162","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024141162/ownership.xml","form_type":"4"}},{"id":1320294,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-12-30T21:30:06.000Z","date":"2024-12-26","kind":"grant","planned":false,"acquired":true,"shares":3200000,"price":0.0005,"value":1600.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 26, 2024, the Reporting Person acquired 3,200,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 26, 2024, the Reporting Person acquired 3,200,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."}],"balance_after":5248903500,"source":{"system":"sec-edgar","filing":"0000950170-24-141162","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024141162/ownership.xml","form_type":"4"}},{"id":1320910,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-12-27T21:30:03.000Z","date":"2024-12-24","kind":"grant","planned":false,"acquired":true,"shares":7500000,"price":0.0005,"value":3750.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 24, 2024, the Reporting Person acquired 7,500,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 24, 2024, the Reporting Person acquired 7,500,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."}],"balance_after":5245703500,"source":{"system":"sec-edgar","filing":"0000950170-24-140807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024140807/ownership.xml","form_type":"4"}},{"id":1321502,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-12-26T21:30:04.000Z","date":"2024-12-23","kind":"grant","planned":false,"acquired":true,"shares":1400000,"price":0.0005,"value":700.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 23, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 23, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."}],"balance_after":5238203500,"source":{"system":"sec-edgar","filing":"0000950170-24-140430","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024140430/ownership.xml","form_type":"4"}},{"id":1321500,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-12-26T21:30:03.000Z","date":"2024-12-20","kind":"grant","planned":false,"acquired":true,"shares":1400000,"price":0.0005,"value":700.0,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 20, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 20, 2024, the Reporting Person acquired 1,400,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share."}],"balance_after":5236803500,"source":{"system":"sec-edgar","filing":"0000950170-24-140427","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024140427/ownership.xml","form_type":"4"}},{"id":1344490,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-12-03T22:50:42.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":419286000,"price":0.0012,"value":503143.2,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The warrants have an exercise price of $0.001130 per Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":419286000,"derivative":{"exercise_price":0.0011,"exercise_date":"2024-12-02","expiration_date":"2027-12-02","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":419286000},"source":{"system":"sec-edgar","filing":"0000950170-24-132936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024132936/ownership.xml","form_type":"4"}},{"id":1344489,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-03T22:50:42.000Z","date":"2024-11-30","kind":"grant","planned":false,"acquired":true,"shares":162604000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The stock options have an exercise price of $0.000615 per Ordinary Share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":162604000,"derivative":{"exercise_price":0.0006,"exercise_date":"2024-11-30","expiration_date":"2034-11-30","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":162604000},"source":{"system":"sec-edgar","filing":"0000950170-24-132936","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024132936/ownership.xml","form_type":"4"}},{"id":1344488,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-12-03T22:50:42.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":419286000,"price":0.0012,"value":503143.2,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant."}],"balance_after":5235403500,"source":{"system":"sec-edgar","filing":"0000950170-24-132936","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024132936/ownership.xml","form_type":"4"}},{"id":1361415,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-11-19T01:02:22.000Z","date":"2024-11-14","kind":"grant","planned":false,"acquired":true,"shares":1404622000,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. (\"Peak Bio\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer (\"Merger Sub\"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding share of common stock of Peak Bio (each, a \"Peak Share\") was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") ADSs."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. (\"Peak Bio\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer (\"Merger Sub\"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding share of common stock of Peak Bio (each, a \"Peak Share\") was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") ADSs."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of Ordinary Shares acquired by the Reporting Person from the exchange of Peak Shares held by the Reporting Person at the Effective Time in accordance with the Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended, by and among the Issuer, Peak Bio Inc. (\"Peak Bio\"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Issuer (\"Merger Sub\"), pursuant to which Merger Sub merged with and into Peak Bio effective as of November 14, 2024, with Peak Bio surviving as a wholly owned subsidiary of the Issuer (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each issued and outstanding share of common stock of Peak Bio (each, a \"Peak Share\") was cancelled and converted into the right to receive 0.2935 (the \"Exchange Ratio\") ADSs."}],"balance_after":4816117500,"source":{"system":"sec-edgar","filing":"0000950170-24-128190","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024128190/ownership.xml","form_type":"4"}},{"id":1378035,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-01T22:00:04.000Z","date":"2024-10-31","kind":"grant","planned":false,"acquired":true,"shares":79684000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The stock options have an exercise price of $0.001255 per ordinary share, par value $0.0001 per share (\"Ordinary Share\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":79684000,"derivative":{"exercise_price":0.0013,"exercise_date":"2024-10-31","expiration_date":"2034-10-31","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":79684000},"source":{"system":"sec-edgar","filing":"0000950170-24-120185","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024120185/ownership.xml","form_type":"4"}},{"id":1393779,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T22:34:33.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":175080000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The stock options have an exercise price of $0.001490 per ordinary share, par value $0.0001 per share (\"Ordinary Share\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":175080000,"derivative":{"exercise_price":0.0015,"exercise_date":"2024-09-30","expiration_date":"2034-09-30","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":175080000},"source":{"system":"sec-edgar","filing":"0000950170-24-111796","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024111796/ownership.xml","form_type":"4"}},{"id":1462175,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-07-02T20:30:08.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":91396000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent restricted stock units (\"RSUs\") granted under the Issuer's 2023 Equity Incentive Plan, with each such RSU representing the right to receive one ordinary share, par value $0.0001. One-hundered percent (100%) of the RSUs vested on the date of grant, or June 30, 2024."}],"balance_after":91396000,"source":{"system":"sec-edgar","filing":"0000950170-24-080542","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024080542/ownership.xml","form_type":"4"}},{"id":1491490,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-06-04T20:45:04.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":1326258000,"price":0.0009,"value":1193632.2,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The warrants have an exercise price of $0.000895 per Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":1326258000,"derivative":{"exercise_price":0.0009,"exercise_date":"2024-05-31","expiration_date":"2027-05-31","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":1326258000},"source":{"system":"sec-edgar","filing":"0000950170-24-068771","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024068771/ownership.xml","form_type":"4"}},{"id":1491489,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001 per share","published_at":"2024-06-04T20:45:04.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":1326258000,"price":0.0009,"value":1193632.2,"ownership":{"direct":false,"nature":"PranaBio Investments LLC"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 31, 2024, the Reporting Person acquired 1,326,258,000 Ordinary Shares and accompanying warrants to purchase up to 1,326,258,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of May 29, 2024. The combined purchase price was $0.0009425 per Ordinary Share and accompanying warrant."}],"balance_after":3411495500,"source":{"system":"sec-edgar","filing":"0000950170-24-068771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024068771/ownership.xml","form_type":"4"}},{"id":2493205,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-30T23:31:51.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":12329,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":12329,"derivative":{"exercise_price":2.25,"exercise_date":"2020-05-31","expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":12329},"source":{"system":"sec-edgar","filing":"0000899243-21-046333","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046333/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-29"}},{"id":2493204,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-30T23:31:51.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":12329,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":0,"derivative":{"exercise_price":2.25,"exercise_date":"2020-05-31","expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":12329},"source":{"system":"sec-edgar","filing":"0000899243-21-046333","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046333/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-29"}},{"id":2493203,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-30T23:31:51.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021."}],"balance_after":225000,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-046333","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046333/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-29"}},{"id":2493202,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-30T23:31:51.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021."}],"balance_after":0,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-046333","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046333/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-29"}},{"id":2493201,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-30T23:31:51.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":112500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":112500,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0000899243-21-046333","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046333/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-29"}},{"id":2493200,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-30T23:31:51.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on December 1, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":0,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-046333","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046333/doc4a.xml","form_type":"4/A","original_submission_date":"2021-11-29"}},{"id":2493934,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-29T23:30:07.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":12329,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":12329,"derivative":{"exercise_price":2.25,"exercise_date":"2020-05-31","expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":12329},"source":{"system":"sec-edgar","filing":"0000899243-21-046250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046250/doc4.xml","form_type":"4"}},{"id":2493933,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-29T23:30:07.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":12329,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":0,"derivative":{"exercise_price":2.25,"exercise_date":"2020-05-31","expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":12329},"source":{"system":"sec-edgar","filing":"0000899243-21-046250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046250/doc4.xml","form_type":"4"}},{"id":2493932,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-29T23:30:07.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021."}],"balance_after":225000,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-046250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046250/doc4.xml","form_type":"4"}},{"id":2493931,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-29T23:30:07.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"56,250 shares vested on August 31, 2020; the balance vested in equal amounts on November 30, 2020, February 28, 2021, and May 31, 2021."}],"balance_after":0,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-046250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046250/doc4.xml","form_type":"4"}},{"id":2493930,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-29T23:30:07.000Z","date":"2021-11-24","kind":"grant","acquired":true,"shares":93750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":93750,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0000899243-21-046250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046250/doc4.xml","form_type":"4"}},{"id":2493929,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-11-29T23:30:07.000Z","date":"2021-11-24","kind":"disposition_to_issuer","acquired":false,"shares":225000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The term of the Reporting Person's Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended (the \"2012 Plan\")) as a director of the Issuer ended as of the conclusion of the Issuer's 2021 Annual Meeting of Stockholders on November 24, 2021. Effective immediately prior to the end of the Reporting Person's Continuous Service, each outstanding stock option that had been granted to the Reporting Person under the 2012 Plan was amended to (a) vest and become immediately exercisable, to the extent it would have become vested on November 30, 2021, with the balance of the unvested portion of such option, if any, immediately forfeited, and (b) cause the option to remain exercisable through the original expiration date instead of terminating 90 days following the end of the Reporting Person's Continuous Service."}],"balance_after":0,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-046250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321046250/doc4.xml","form_type":"4"}},{"id":2538582,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2021-10-20T20:10:49.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in 12 equal monthly installments beginning on July 1, 2021, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date."}],"balance_after":225000,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000899243-21-040748","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321040748/doc4.xml","form_type":"4"}},{"id":3099483,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified Stock Option","published_at":"2020-06-27T01:47:09.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"56,250 shares vest on August 31, 2020; the balance vests in equal amounts on November 30, 2020, February 28, 2021 and May 31, 2021, subject to amendment to the equity incentive plan."}],"balance_after":225000,"derivative":{"exercise_price":6.15,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001807094-20-000012","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000012/primary_doc.xml","form_type":"4"}},{"id":3172122,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":29698,"kind":"person","name":"Patel Samir Rashmikant","position":1,"cik":"0001702447","reported_name":"Patel Samir Rashmikant","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-04-22T21:37:58.000Z","date":"2020-04-17","kind":"grant","acquired":true,"shares":12329,"price":2.25,"value":27740.25,"ownership":{"direct":true},"balance_after":12329,"derivative":{"exercise_price":2.25,"exercise_date":"2020-05-31","expiration_date":"2030-04-17","underlying":"Common Stock","underlying_shares":12329},"source":{"system":"sec-edgar","filing":"0001702447-20-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000170244720000004/primary_doc.xml","form_type":"4"}}]}